261 related articles for article (PubMed ID: 30294590)
21. Clinical Applications of Cerebrospinal Fluid Circulating Tumor DNA as a Liquid Biopsy for Central Nervous System Tumors.
Yan W; Xu T; Zhu H; Yu J
Onco Targets Ther; 2020; 13():719-731. PubMed ID: 32158224
[TBL] [Abstract][Full Text] [Related]
22. Comparative Molecular Analysis of Primary Central Nervous System Lymphomas and Matched Vitreoretinal Lymphomas by Vitreous Liquid Biopsy.
Balikov DA; Hu K; Liu CJ; Betz BL; Chinnaiyan AM; Devisetty LV; Venneti S; Tomlins SA; Cani AK; Rao RC
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576156
[TBL] [Abstract][Full Text] [Related]
23. MYD88 L265P Mutation Detection by ddPCR: Recommendations for Screening and Minimal Residual Disease Monitoring : ddPCR for Highly Sensitive Detection of MYD88 L265P Mutation.
Drandi D; Ferrante M; Borriero M; Ferrero S
Methods Mol Biol; 2023; 2621():57-72. PubMed ID: 37041440
[TBL] [Abstract][Full Text] [Related]
24. Circulating cell-free DNA and IL-10 from cerebrospinal fluids aid primary vitreoretinal lymphoma diagnosis.
Zhuang Z; Zhang Y; Zhang X; Zhang M; Zou D; Zhang L; Jia C; Zhang W
Front Oncol; 2022; 12():955080. PubMed ID: 36059608
[TBL] [Abstract][Full Text] [Related]
25.
Narasimhan S; Joshi M; Parameswaran S; Rishi P; Khetan V; Ganesan S; Biswas J; Sundaram N; Sreenivasan J; Verma S; Krishnamurthy V; Subramanian K
Indian J Ophthalmol; 2020 Oct; 68(10):2160-2165. PubMed ID: 32971631
[TBL] [Abstract][Full Text] [Related]
26. Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma.
Yoon SE; Kim YJ; Shim JH; Park D; Cho J; Ko YH; Park WY; Mun YC; Lee KE; Cho D; Kim WS; Kim SJ
Cancer Res Treat; 2022 Apr; 54(2):597-612. PubMed ID: 34325497
[TBL] [Abstract][Full Text] [Related]
27. Evaluating the cerebrospinal fluid ctDNA detection by next-generation sequencing in the diagnosis of meningeal Carcinomatosis.
Zhao Y; He JY; Zou YL; Guo XS; Cui JZ; Guo L; Bu H
BMC Neurol; 2019 Dec; 19(1):331. PubMed ID: 31856745
[TBL] [Abstract][Full Text] [Related]
28. Current Role and Future Potential of CSF ctDNA for the Diagnosis and Clinical Management of Pediatric Central Nervous System Tumors.
Miller AM; Karajannis MA
J Natl Compr Canc Netw; 2022 Dec; 20(12):1363-1369. PubMed ID: 36509077
[TBL] [Abstract][Full Text] [Related]
29. Prevalence And Clinical Significance Of Oncogenic
Chen YP; Ke LF; Lu JP; Wang JC; Zhu WF; Chen FF; Lin SF; Xu CW; Wu MJ; Chen G
Onco Targets Ther; 2019; 12():10165-10175. PubMed ID: 32063711
[TBL] [Abstract][Full Text] [Related]
30. The genomic and transcriptional landscape of primary central nervous system lymphoma.
Radke J; Ishaque N; Koll R; Gu Z; Schumann E; Sieverling L; Uhrig S; Hübschmann D; Toprak UH; López C; Hostench XP; Borgoni S; Juraeva D; Pritsch F; Paramasivam N; Balasubramanian GP; Schlesner M; Sahay S; Weniger M; Pehl D; Radbruch H; Osterloh A; Korfel A; Misch M; Onken J; Faust K; Vajkoczy P; Moskopp D; Wang Y; Jödicke A; Trümper L; Anagnostopoulos I; Lenze D; Küppers R; Hummel M; Schmitt CA; Wiestler OD; Wolf S; Unterberg A; Eils R; Herold-Mende C; Brors B; ; Siebert R; Wiemann S; Heppner FL
Nat Commun; 2022 May; 13(1):2558. PubMed ID: 35538064
[TBL] [Abstract][Full Text] [Related]
31. MYD88 L265P mutation in primary central nervous system lymphoma is associated with better survival: A single-center experience.
Curran OE; Poon MTC; Gilroy L; Torgersen A; Smith C; Al-Qsous W
Neurooncol Adv; 2021; 3(1):vdab090. PubMed ID: 34377990
[TBL] [Abstract][Full Text] [Related]
32. MYD88
Chen R; Zhou D; Wang L; Zhu L; Ye X
Ther Adv Hematol; 2022; 13():20406207211072839. PubMed ID: 35126963
[TBL] [Abstract][Full Text] [Related]
33. Pathology and new insights in central nervous system lymphomas.
Lebrun L; Allard-Demoustiez S; Salmon I
Curr Opin Oncol; 2023 Sep; 35(5):347-356. PubMed ID: 37439536
[TBL] [Abstract][Full Text] [Related]
34. Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis.
King RL; Goodlad JR; Calaminici M; Dotlic S; Montes-Moreno S; Oschlies I; Ponzoni M; Traverse-Glehen A; Ott G; Ferry JA
Virchows Arch; 2020 May; 476(5):647-665. PubMed ID: 31863183
[TBL] [Abstract][Full Text] [Related]
35. Applications of cerebrospinal fluid circulating tumor DNA in the diagnosis of gliomas.
Zhao Z; Zhang C; Li M; Shen Y; Feng S; Liu J; Li F; Hou L; Chen Z; Jiang J; Ma X; Chen L; Yu X
Jpn J Clin Oncol; 2020 Mar; 50(3):325-332. PubMed ID: 32039443
[TBL] [Abstract][Full Text] [Related]
36. Liquid biopsy for pediatric diffuse midline glioma: a review of circulating tumor DNA and cerebrospinal fluid tumor DNA.
Azad TD; Jin MC; Bernhardt LJ; Bettegowda C
Neurosurg Focus; 2020 Jan; 48(1):E9. PubMed ID: 31896079
[TBL] [Abstract][Full Text] [Related]
37. Gene expression profiling of primary vitreoretinal lymphoma.
Arai A; Takase H; Yoshimori M; Yamamoto K; Mochizuki M; Miura O
Cancer Sci; 2020 Apr; 111(4):1417-1421. PubMed ID: 32056332
[TBL] [Abstract][Full Text] [Related]
38. Beyond the Blood: CSF-Derived cfDNA for Diagnosis and Characterization of CNS Tumors.
McEwen AE; Leary SES; Lockwood CM
Front Cell Dev Biol; 2020; 8():45. PubMed ID: 32133357
[TBL] [Abstract][Full Text] [Related]
39. Cerebrospinal fluid circulating tumour DNA as a liquid biopsy for central nervous system malignancies.
Escudero L; Martínez-Ricarte F; Seoane J
Curr Opin Neurol; 2020 Dec; 33(6):736-741. PubMed ID: 33177377
[TBL] [Abstract][Full Text] [Related]
40. ctDNA-Based Liquid Biopsy of Cerebrospinal Fluid in Brain Cancer.
Escudero L; Martínez-Ricarte F; Seoane J
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33919036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]